Aurobindo Pharma to cease molnupiravir trial in average COVID-19 sufferers, Well being Information, ET HealthWorld


Aurobindo Pharma to stop molnupiravir trial in moderate COVID-19 patientsBENGALURU: Aurobindo Pharma Ltd needs to discontinue the late-stage trial of Merck & Co’s experimental antiviral drug molnupiravir in average COVID-19 sufferers, the Indian drug regulator’s knowledgeable committee mentioned on Friday.

Observe and join with us on , Fb, Linkedin





Supply hyperlink

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Translate » Hindi